<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01313182</url>
  </required_header>
  <id_info>
    <org_study_id>11318</org_study_id>
    <nct_id>NCT01313182</nct_id>
  </id_info>
  <brief_title>Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>3M</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>3M</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize the application of mupirocin or povidone-iodine to the nares is equally
      effective in short term Staphylococcus aureus(SA)suppression. Our overall study objective is
      to measure the rate of deep and superficial Surgical Site Infections (SSIs) after primary
      hip, knee, shoulder and elbow arthroplasty surgery and primary spinal fusion surgery
      requiring implantation of prosthetic material, when the patient receives either nasal
      mupirocin or nasal povidone-iodine prior to surgery.

      Secondary study objectives include:

        1. Measure hospital length of stay and re-admission rates in the mupirocin and
           povidone-iodine groups.

        2. Measure adverse events related to mupirocin and povidone-iodine.

        3. Measure rate of SA resistance to mupirocin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical Site Infections Occurring Within 12 Months of Surgical Procedure</measure>
    <time_frame>12 months</time_frame>
    <description>Measure the rate (number and percent of patients) with deep and superficial surgical site infections after primary orthopedic surgery and primary spinal fusion surgery requiring implantation of prosthetic material.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure Hospital Length of Stay and Re-admission Rates in the Mupirocin and Povidone-iodine Groups.</measure>
    <time_frame>12 months</time_frame>
    <description>Re-admission for infection within 12 months of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Adverse Events Related to Mupirocin and Povidone-iodine.</measure>
    <time_frame>At time of treatment</time_frame>
    <description>Patients were given an adverse event log to complete after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.</measure>
    <time_frame>Isolates collected and frozen</time_frame>
    <description>Lab will culture isolates when time and money permit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1784</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>3M Skin and Nasal Antiseptic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bactroban Nasal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mupirocin calcium ointment, 2%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mupirocin calcium ointment, 2%</intervention_name>
    <description>Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.</description>
    <arm_group_label>Bactroban Nasal</arm_group_label>
    <other_name>Bactroban Nasal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation</intervention_name>
    <description>The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.</description>
    <arm_group_label>3M Skin and Nasal Antiseptic</arm_group_label>
    <other_name>3M Skin and Nasal Antiseptic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary arthroplasty or spinal fusion surgery

          -  Age greater than 18 years

        Exclusion Criteria:

          -  Revision arthroplasty

          -  Revision spinal fusion surgery

          -  Primary spine surgery without implantation of prosthetic material

          -  Allergy to mupirocin

          -  Allergy to povidone-iodine

          -  Pregnancy

          -  Breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Phillips, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2011</study_first_submitted>
  <study_first_submitted_qc>March 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <results_first_submitted>February 21, 2014</results_first_submitted>
  <results_first_submitted_qc>April 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2014</results_first_posted>
  <last_update_submitted>April 24, 2014</last_update_submitted>
  <last_update_submitted_qc>April 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
    <mesh_term>Povidone-Iodine</mesh_term>
    <mesh_term>Anti-Infective Agents, Local</mesh_term>
    <mesh_term>Mupirocin</mesh_term>
    <mesh_term>Povidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Only patients receiving surgery were considered Started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>3M Skin and Nasal Antiseptic</title>
          <description>Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.</description>
        </group>
        <group group_id="P2">
          <title>Bactroban Nasal</title>
          <description>Mupirocin calcium ointment, 2%
mupirocin calcium ointment, 2%: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="842"/>
                <participants group_id="P2" count="855"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="776"/>
                <participants group_id="P2" count="763"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="92"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>arthroplasty or spine fusion surgery patients</population>
      <group_list>
        <group group_id="B1">
          <title>3M Skin and Nasal Antiseptic</title>
          <description>Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.</description>
        </group>
        <group group_id="B2">
          <title>Bactroban Nasal</title>
          <description>Mupirocin calcium ointment, 2%
mupirocin calcium ointment, 2%: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="842"/>
            <count group_id="B2" value="855"/>
            <count group_id="B3" value="1697"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.8" lower_limit="19.1" upper_limit="92.4"/>
                    <measurement group_id="B2" value="62.4" lower_limit="19.2" upper_limit="93.2"/>
                    <measurement group_id="B3" value="62.1" lower_limit="19.1" upper_limit="93.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="499"/>
                    <measurement group_id="B2" value="523"/>
                    <measurement group_id="B3" value="1022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="842"/>
                    <measurement group_id="B2" value="855"/>
                    <measurement group_id="B3" value="1697"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Surgical Site Infections Occurring Within 12 Months of Surgical Procedure</title>
        <description>Measure the rate (number and percent of patients) with deep and superficial surgical site infections after primary orthopedic surgery and primary spinal fusion surgery requiring implantation of prosthetic material.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>3M Skin and Nasal Antiseptic</title>
            <description>Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.</description>
          </group>
          <group group_id="O2">
            <title>Bactroban Nasal</title>
            <description>Mupirocin calcium ointment, 2%
mupirocin calcium ointment, 2%: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.</description>
          </group>
        </group_list>
        <measure>
          <title>Surgical Site Infections Occurring Within 12 Months of Surgical Procedure</title>
          <description>Measure the rate (number and percent of patients) with deep and superficial surgical site infections after primary orthopedic surgery and primary spinal fusion surgery requiring implantation of prosthetic material.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="776"/>
                <count group_id="O2" value="763"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Hospital Length of Stay and Re-admission Rates in the Mupirocin and Povidone-iodine Groups.</title>
        <description>Re-admission for infection within 12 months of procedure</description>
        <time_frame>12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Adverse Events Related to Mupirocin and Povidone-iodine.</title>
        <description>Patients were given an adverse event log to complete after treatment</description>
        <time_frame>At time of treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Rate of Staphylococcus Aureus Resistance to Mupirocin.</title>
        <description>Lab will culture isolates when time and money permit</description>
        <time_frame>Isolates collected and frozen</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3M Skin and Nasal Antiseptic</title>
          <description>Povidone-iodine solution 5% w/w (0.5% available iodine) USP Patient Preoperative Skin Preparation
Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.</description>
        </group>
        <group group_id="E2">
          <title>Bactroban Nasal</title>
          <description>Mupirocin calcium ointment, 2%
mupirocin calcium ointment, 2%: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="855"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="842"/>
                <counts group_id="E2" subjects_affected="76" subjects_at_risk="855"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="842"/>
                <counts group_id="E2" events="47" subjects_affected="47" subjects_at_risk="855"/>
              </event>
              <event>
                <sub_title>Nasal irritation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="842"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="855"/>
              </event>
              <event>
                <sub_title>Congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="842"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="855"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="842"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="855"/>
              </event>
              <event>
                <sub_title>Pharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="842"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="855"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="842"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="855"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study failed to achieve target enrollment. The small sample size precluded a multivariate analysis. Nasal culture alone was used as a screen for S. aureus colonization, which has a sensitivity of only 48% to 66%.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Michael Phillips</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>212 263 4316</phone>
      <email>michael.phillips@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

